Monitor the company's cash position and future filings for actual issuance of shares under the approved plans. No immediate catalyst; the filing is routine governance.
Price Chart
Executive Summary
Valion Bio held its 2026 annual meeting on May 28, 2026. Shareholders approved an amendment to the 2021 Equity Incentive Plan increasing authorized shares by 2,581,608, ratified the appointment of Rosenberg Rich Baker Berman as independent auditor, and approved several stock issuance proposals related to prior convertible note and warrant agreements. No material financial events or executive changes were reported.
Key Facts
- Stockholders approved a 2,581,608 share increase under the 2021 Equity Incentive Plan.
- Rosenberg Rich Baker Berman was ratified as independent auditor for fiscal 2026.
- Approved issuance of shares upon conversion of Series C Preferred Stock and related warrants.
- Approved issuance of shares upon conversion of Senior Secured Convertible Note and warrant to 3i, LP.
- Approved issuance of shares upon conversion of Series B Preferred Stock and related warrants to 3i, LP.
- Approved sale/issuance of shares under Common Stock Purchase Agreement with Tumim Stone Capital, LLC.
Financial Impact
Potential future dilution from approved share issuances under existing agreements; exact amounts not disclosed.
Risk Factors
- Potential dilution from conversion of preferred stock, convertible notes, and warrants.
- Low market cap ($2M) increases sensitivity to any dilution.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001683168-26-004481 |
| Document: valion_ex1001.htm | 0001683168-26-004481 |
| Document: 0001683168-26-004481-index-headers.html | 0001683168-26-004481 |
| Document: 0001683168-26-004481-index.html | 0001683168-26-004481 |
| Document: 0001683168-26-004481.txt | 0001683168-26-004481 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $0.8950 | awaiting T+20 | — | $0.8253 (+7.79%) |
Oct 26, 2026 1d ago | 8-K | $1.15 | awaiting T+20 | — | $0.8253 (−27.98%) |
Oct 22, 2026 5d ago | 8-K | $0.9560 | awaiting T+20 | — | $0.8253 (−13.67%) |
Oct 21, 2026 6d ago | EFFECT | $1.12 | awaiting T+20 | — | $0.8253 (+26.31%) |
Oct 21, 2026 6d ago | EFFECT | $1.12 | awaiting T+20 | — | $0.8253 (+26.31%) |
Oct 16, 2026 10d ago | S-3 | $1.16 | awaiting T+20 | — | $0.8253 (+28.85%) |
Oct 16, 2026 10d ago | DEF 14A | $1.16 | awaiting T+20 | — | $0.8253 (+28.85%) |
Oct 15, 2026 12d ago | 8-K | $1.23 | awaiting T+20 | — | $0.8253 (−32.90%) |
Oct 14, 2026 13d ago | 8-K | $1.45 | awaiting T+20 | — | $0.8253 (−43.08%) |
Oct 8, 2026 19d ago | 8-K | $2.21 | awaiting T+20 | — | $0.8253 (+62.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers